For the main analyses, differences in HRU at the 120-day follow-up will be determined by comparing the mean number of hospitalizations, emergency room visits, diagnostic procedures, surgical procedures, and clinic visits between the tested and untested groups. The impact of YouScript on clinical decision making will be determined by comparing the mean number of changes in drug regimen or dose between those who underwent YouScript testing and those that did not. In addition, the number of ADEs experienced by patients during the 120-day study will be compared between the tested and untested groups. Comparisons will be made with the t-test (if the data are normally distributed), the Wilcoxon-Rank-Sum test (if the data are continuous and not normally distributed), or the chi-squared (or Fisher exact) test if the data are considered categorical. Multivariable linear regression models will be used to examine the association of the YouScript Personalized Prescribing System with HRU, clinical decision making, and ADEs, respectively, while controlling for potential confounding effects from baseline characteristics not included in the propensity score matching process.